Clinical Trial Update: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating physical activity and joint health in severe Hemophilia A patients aged 12 and older treated weekly with efanesoctocog alfa has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia A Severe

Drugs mentioned

• Efanesoctocog alfa (efanesoctocog alfa)

Snippet

Sponsor: Swedish Orphan Biovitrum | Conditions: Hemophilia A, Severe | Phase 3 | Status: COMPLETED